<DOC>
	<DOCNO>NCT00489372</DOCNO>
	<brief_summary>This randomized phase I trial study side effect best dose Se-methyl-seleno-L-cysteine healthy adult men . Studying sample blood , urine , toenail clipping laboratory healthy men receive Se-methyl-seleno-L-cysteine may help doctor learn Se-methyl-seleno-L-cysteine work body .</brief_summary>
	<brief_title>Se-Methyl-Seleno-L- Cysteine ( MSC ) Treating Healthy Patients</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate toxicity MSC , give healthy adult male single oral dose . SECONDARY OBJECTIVES : I . To characterize pharmacokinetics single oral dos MSC healthy adult male volunteer . II . To evaluate baseline selenium content toenail clipping healthy adult male . OUTLINE : This multicenter , randomize , placebo control , double blind , dose escalation study . Participants randomize 1 2 arm . Arm I : Participants receive oral placebo day 1 . Arm II : Participants receive oral Se-methyl-seleno-l-cysteine ( MSC ) day 1 . Cohorts 5 participant receive escalate dos MSC maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 5 2 10 patient experience dose-limiting toxicity . Participants undergo blood , urine , toenail clip collection pharmacokinetic correlative study . Samples analyze plasma protein level selenium proteomic gene expression , molecular fingerprint mass spectrometry , RNA gene array analysis . After completion study treatment , participant follow 7-14 day 30 day .</detailed_description>
	<mesh_term>Selenomethylselenocysteine</mesh_term>
	<criteria>Total body weight 50 115 kg Hgb &gt; 12 gm/dl Platelets &gt; 100,000/μL ANC &gt; 1000/μL Creatinine &lt; 1.5 mg/dl SGPT SGOT &lt; 3 X institutional upper limit normal ( ULN ) Total bilirubin &lt; 1.5 X institutional ULN ( subject high level bilirubin due familial metabolism consider individual basis ) Life expectancy great 2 year Male subject must agree use adequate contraception ( barrier method birth control ; abstinence ) prior study entry study completion ( i.e. , least two week dose study drug ) Ability understand willingness sign write informed consent document Agree refrain use selenium supplement study Not willing remain RPCI , follow , require Presence medical condition , opinion investigator , would compromise either subject , integrity data Individuals history active liver kidney disease within past 6 month Treatment investigational drug within 30 day prior dose study drug Use prescription nonprescription drug , vitamin , herbal supplement know change gastric acidity ( e.g. , H2antagonists , proton pump inhibitor , antacid ) within 3 day study drug administration History allergic reaction attribute compound similar chemical biologic composition MSC ( e.g . reaction selenium supplement ) Subjects donate 1 unit blood within 30 day prior first dose MSC Subjects know history heavy metal exposure , lead , mercury , arsenic ECOG performance status &gt; 1 AUA total symptom score &gt; 10 ( individual symptom score great equal 4 exclude participant )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>